Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 10/20 | 0.57 |
| ▸ | CLK2 | P49760 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930559 | 0.92 | NPC1 (0.60) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL2927267 | 0.89 | NPC1 (0.61) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL2927215 | 0.88 | HPGD (0.55) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL2926183 | 0.82 | L3MBTL1 (0.41) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL14022343 | 0.81 | RAB9A (0.67) | NPC1RAB9AHPGDSMN1; SMN2CLK2 | |
| SCHEMBL2927703 | 0.80 | NPC1 (0.60) | NPC1RAB9AMAOBCLK2CLK4 | |
| SCHEMBL18146208 | 0.79 | MDM2 (0.55) | NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2932098 | 0.78 | HPGD (0.65) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL15764689 | 0.78 | NPC1 (0.70) | NPC1RAB9AHPGDSMN1; SMN2MAOB | |
| SCHEMBL9944803 | 0.77 | CYP2C19 (0.52) | NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| CN-102633783-A | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA INC | 2012-08-15 | — | — | CN | disclosed |
| CN-101379060-B | Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use | TRANSTECH PHARMA INC | 2012-05-23 | — | — | CN | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| CN-101379060-A | Benzoxazole-based derivatives as Aurora kinase inhibitors, compositions, and methods of use | TRANSTECH PHARMA INC (US) | 2009-03-04 | — | — | CN | disclosed |
| EP-1987028-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
| WO-2007095124-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | NPC1 653/4885RAB9A 3858/4885HPGD 3750/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | NPC1 653/4885RAB9A 3858/4885HPGD 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.